Methuselah

Methuselah (玛士撒拉) is a Chinese medical-nutrition brand focused on the aging economy, per FreeS Fund's reporting, with a product line spanning special medical purpose foods, low-GI, and calorie-controlled weight-management products; as of FreeS's March 2024 write-up it had entered over 700 top-tier (三甲) hospitals and served more than 10 million patients . FreeS backed it at Series A and kept adding through later rounds: a near-100M RMB A+ led by Jinding Capital in mid-2023, a near-200M RMB Series B in early 2025 co-led by a CICC Capital fund, Hongsheng Capital and Hony (弘晖) fund, and a 100M-plus RMB B+ in late 2025 co-led by Bailian's investment arms . Note the latest round info comes from a November 2025 FreeS funding digest; elsewhere's corpus has no deeper independent profile of the company beyond FreeS's own coverage.